Omidubicel对比标准清髓性脐带血移植:3期随机研究结果
该3期随机试验纳入125例13至65岁血液恶性肿瘤患者,比较omidubicel与标准脐带血移植的疗效。Omidubicel组血小板恢复更快、早期感染更少、移植后100天内住院时间更短,移植物抗宿主病(GVHD)和生存无显著差异。
要点
- Omidubicel组中性粒细胞植入中位时间12天,显著快于对照组的22天
- Omidubicel组42天血小板恢复率55%,高于对照组的35%
- Omidubicel组首次2-3级细菌或侵袭性真菌感染发生率37%,低于对照组的57%
核心结论
- Omidobicel移植较标准脐带血移植造血恢复更快,并减少早期移植相关并发症。
- 结果提示omidubicel或可成为适合脐带血移植成人患者的新标准治疗选择。
研究设计与样本
- 3期随机对照试验,2017年1月至2020年1月纳入125例13至65岁血液恶性肿瘤患者。
- 患者随机分配至omidubicel组或标准脐带血移植组,均接受清髓性预处理。
- GVHD预防采用钙调神经磷酸酶抑制剂联合吗替麦考酚酯。
- 主要终点为中性粒细胞植入时间。
- 试验注册号NCT02730299。
主要发现
- 中性粒细胞植入累积发生率:omidubicel组96%,对照组89%。
临床怎么用
- 对于适合脐带血移植的成人血液恶性肿瘤患者,可考虑omidubicel以加速造血恢复。
- Omidubicel可能减少早期感染并缩短移植后住院时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Omidubicel is an ex vivo expanded hematopoietic progenitor cell and nonexpanded myeloid and lymphoid cell product derived from a single umbilical cord blood unit. We report results of a phase 3 trial to evaluate the efficacy of omidubicel compared with standard umbilical cord blood transplantation (UCBT). Between January 2017 and January 2020, 125 patients age 13 to 65 years with hematologic malignancies were randomly assigned to omidubicel vs standard UCBT. Patients received myeloablative conditioning and prophylaxis with a calcineurin inhibitor and mycophenolate mofetil for graft-versus-host disease (GVHD). The primary end point was time to neutrophil engraftment. The treatment arms were well balanced and racially diverse. Median time to neutrophil engraftment was 12 days (95% confidence interval [CI], 10-14 days) for the omidubicel arm and 22 days (95% CI, 19-25 days) for the control arm (P < .001). The cumulative incidence of neutrophil engraftment was 96% for patients receiving omidubicel and 89% for patients receiving control transplants. The omidubicel arm had faster platelet recovery (55% vs 35% recovery by 42 days; P = .028), had a lower incidence of first grade 2 to 3 bacterial or invasive fungal infection (37% vs 57%; P = .027), and spent more time out of hospital during the first 100 days after transplant (median, 61 vs 48 days; P = .005) than controls. Differences in GVHD and survival between the 2 arms were not statistically significant. Transplantation with omidubicel results in faster hematopoietic recovery and reduces early transplant-related complications compared with standard UCBT. The results suggest that omidubicel may be considered as a new standard of care for adult patients eligible for UCBT. The trial was registered at www.clinicaltrials.gov as #NCT02730299.
引用
- Horwitz ME, Stiff PJ, Cutler C, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021. PMID: 34157093. doi:10.1182/blood.2021011719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。